Our Intellectual Property

Patents have been granted in the United States, Europe (the United Kingdom, Germany, France & Italy), Japan, China, India, Brazil, South Africa, Canada, Australia, Hong Kong and Singapore and New Zealand.

The table below sets out the status of the granted patents in the various jurisdictions in which we have patent protection of the OPAL Process and Products.

We believe that we have strong patent protection against competitor products made from fruits and vegetables, and in particular Carica papaya (paw paw), where the active ingredients are produced and/or made more active by the same chemical transformation of the fruit or vegetable that occurs in the OPAL Process.

Broad Claims in a Crowded Field

There is voluminous literature and thousands of patents for natural therapeutic and cosmetic products and their uses, making this field extremely crowded. Despite this, we have been able to obtain patents in China, India, Brazil, South Africa, Canada, Australia, Singapore and New Zealand over compositions derived from all fruits and vegetables that have been alkalised.

Future Patents

Our clinical data and scientific study results suggest that OPAL A has powerful therapeutic and cosmetic properties. This data further suggests that ongoing rigorous research into the alkalisation of fruits and vegetables undertaken to understand the science behind this invention will lead to the formulation of improved OPAL Products and give rise to future patents.

Significantly, potentially new patentable material has already been created by the scientific work undertaken on Carica papaya, including the identification of a family of chemical entities that are thought to be responsible for one or more of the therapeutic properties suggested by the clinical evidence. The current program of scientific work is primarily directed to securing the support required to meet the requirements for patentability of a pharmaceutical product derived from Carica papaya with one or more named chemical entities and with enhanced therapeutic properties compared to OPAL A.

Recent results from the test work are reported by the globally recognised scientist supervising the work as being “remarkable and unexpected”.

This work is also expected to generate data that would support the regulatory approval of OPAL A as a pharmaceutical drug.

Global Patent Status

All of the granted patents protect the OPAL A Process, the OPAL A Products and the Uses of the OPAL A Products until July 2023.

Granted Claims

Carica
papaya
Fruits & Vegs
referred to in
Specification
All
Fruits
& Vegs
Method
of
Manufacture
Compositions
Made
by Process
Compositions
of alkalised
Fruits & Vegs
Methods
of
Use
United States yes no no yes yes no yes
Europe yes yes no yes yes yes yes
Japan yes no no yes yes no yes
China yes yes yes yes yes no yes
India yes yes yes yes yes no yes
Brazil yes yes yes yes yes yes yes
South Africa yes yes yes yes yes yes yes
Canada yes yes yes yes yes yes yes
Australia yes yes yes yes yes yes yes
Hong Kong yes yes no yes yes yes yes
Singapore yes yes yes yes yes yes yes
New Zealand yes yes yes yes yes yes yes

Explanation of Different Types of Claims

Carica papaya Claims extend to Carica papaya (paw paw) and protect OPAL A.
Fruits & vegetables referred to in Specification Claims extend to all of the fruits and vegetables referred to in the patent application specification that was filed.
All fruits and vegetables Claims extend to all fruits and vegetables.
Method of Manufacture Claims protect the OPAL Process.
Compositions Made by Process Claims protect the OPAL Products created by the OPAL Process.
Compositions of alkalised fruits and vegetables Claims protect all products made from fruit and vegetables if the pH of the product is between 7.5 and 9.5.
Methods of Use Claims protect the use of OPAL Products for treating and preventing dermatological disorders and for treating pain.

Pending Applications

Divisional applications have been filed in the United States. Europe, Japan, China, India and New Zealand to prosecute claims not yet allowed.

Divisional applications have also been filed in Brazil, Australia and Singapore so that additional claims can be filed in the future.